Skip to main content

Advertisement

Table 9 The impact of metabolic phenotypes on prognosis by univariate analysis

From: Metabolic phenotypes in primary unknown metastatic carcinoma

Clinicopathologic parameters No. of patients (n = 59*) (%) Overall survival
No. of cases Patient death Median survival (95% CI) (months) P -value
Tumor metabolic type     0.279
 Glycolysis type 22 5 52 (37–67)  
 Non-glycolysis type 37 13 79 (56–102)  
Tumor metabolic type     0.644
 Glutaminolysis type 30 10 84 (60–108)  
 Non-glutaminolysis type 29 8 45 (30–59)  
Tumor metabolic type     0.906
 Mitochondrial type 56 17 84 (66–103)  
 Non-mitochondrial type 3 1 28 (13–43)  
Stroma metabolic type     n/a
 Glycolysis type 2 0 n/a  
 Non-glycolysis type 57 18 n/a  
Stroma metabolic type     0.363
 Glutaminolysis type 7 1 62 (43–80)  
 Non-glutaminolysis type 52 17 80 (60–100)  
Stroma metabolic type     0.864
 Mitochondrial type 9 2 28 (18–37)  
 Non-mitochondrial type 50 16 83 (64–103)  
  1. * Out of 77 patients, clinical follow-up data were available in 59 patients.